Advertisement
Pharma/Biotech News
Subscribe to Pharma/Biotech News
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Inovio Kicks Off Study of Cervical Cancer Immunotherapy

June 23, 2014 2:13 pm | News | Comments

Inovio Pharmaceuticals Inc. announced it has initiated a Phase 1/2a clinical trial to evaluate safety, immunogenicity, clinical responses and disease-free survival of its DNA immunotherapy product, INO-3112, in treating human papillomavirus (HPV)-associated cervical cancer. Read more...

FDA Approves Cubist’s Skin Infection Antibiotic

June 23, 2014 2:08 pm | News | Comments

Cubist Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) approved Sivextro (tedizolid phosphate) for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Read more...

Shire Rejects AbbVie’s Unsolicited Offer

June 23, 2014 2:02 pm | News | Comments

Takeover target Shire highlighted its potential as a standalone drugmaker, offering investors a rosy projection of its earnings potential that it believes is not reflected in the acquisition proposal made by U.S.-based rival AbbVie. Read more...  

Advertisement

Pharnext's Neuromuscular Disorder Drug Designated Orphan Drug

June 23, 2014 11:45 am | News | Comments

Pharnext SAS announced that the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designation to PXT-3003 for the treatment of Charcot-Marie-Tooth disease type 1A (CMT 1A) in recognition of the value this novel oral therapeutic could bring to these patients. Read more...

Novo Nordisk Posts Positive Phase 3 Data for Obesity Trial

June 23, 2014 11:39 am | News | Comments

New data from the phase 3a SCALE Obesity and Prediabetes trial were presented at the International Congress of Endocrinology and the Endocrine Society’s meeting, showing that in addition to a greater body-weight loss, significantly fewer people with obesity and normal blood glucose at baseline progressed to prediabetes with liraglutide 3 mg treatment at 56 weeks, compared with placebo. Read more...

BI Kicks Off Pradaxa First Ablation Trial

June 23, 2014 11:31 am | News | Comments

Boehringer Ingelheim announced the initiation of a new international study of Pradaxa (dabigatran etexilate mesylate) that will evaluate uninterrupted treatment with Pradaxa, compared to warfarin, in patients with paroxysmal or persistent non-valvular atrial fibrillation (NVAF) who are scheduled to undergo a first ablation procedure. Read more...

Merck Starts Tender Offer for Idenix

June 23, 2014 11:24 am | News | Comments

Merck started a tender offer to buy all of the outstanding shares of hepatitis C treatment maker Idenix Pharmaceuticals Inc., hoping that teaming Idenix's hepatitis C medicines with its experimental drugs will produce lucrative combo therapies. Read more...

Keeping the Lid on R&D Costs

June 23, 2014 11:14 am | by Nancy Dreyfus, Contributing Science Writer | Articles | Comments

In the past, pharmaceutical companies bolstered profits with billion-dollar blockbuster drugs that treated large populations for common conditions, but with patents running out, and development costs soaring, that business model may no longer be sustainable. Read more...

Advertisement

Allergan Calls Valeant Bid “Grossly Inadequate”

June 23, 2014 11:03 am | News | Comments

Allergan, the maker of Botox, said Monday that Valeant Pharmaceuticals' hostile takeover bid for the company is "grossly inadequate," that it is not in the best interest of Allergan's shareholders, and that shareholders should reject it. Read more...

New Therapeutic Target Identified in Atherosclerosis

June 19, 2014 7:18 pm | News | Comments

A new driver of atherosclerosis has been identified by researchers at UT Southwestern Medical Center. This molecule, known as 27HC (27-hydroxycholesterol), has been found to exacerbate the development of the condition, and may prove to be a promising therapeutic target. Read more...

Scientists Discover Molecular ‘Yin-Yang’ of Blood Vessel Growth

June 19, 2014 7:05 pm | News | Comments

Biologists at The Scripps Research Institute (TSRI) have discovered a crucial process that regulates the development of blood vessels, which could lead to new treatments for disorders involving abnormal blood vessel growth, including common disorders such as diabetic retinopathy and cancer. Read more...

GlycoMimetics Kicks Off Clinical Trials of Leukemia Drug

June 19, 2014 6:58 pm | News | Comments

GlycoMimetics Inc. announced that the first healthy volunteer has been dosed in a Phase 1 clinical study designed to evaluate the safety, tolerability and pharmacokinetics of GMI-1271, a novel and proprietary E-selectin antagonist in the company's pipeline. Read more...

Researchers Map Mouse Brain to Understand Brain Disorders

June 19, 2014 6:54 pm | News | Comments

Researchers at the Allen Institute for Brain Science have mapped the development of the mouse brain from the embryo to the adult, creating a preliminary genetic key that allows them to pinpoint the age and location of regions of the developing brain. Read more...

Advertisement

Naloxegol Improves Opioid-Induced Constipation

June 19, 2014 6:44 pm | News | Comments

AstraZeneca announced that The New England Journal of Medicine (NEJM) has published results of two pivotal Phase 3 studies - KODIAC-4 and KODIAC-5 of naloxegol, an investigational treatment for opioid-induced constipation (OIC). Read more...

Research Reveals Gene’s Role in Diabetes

June 19, 2014 6:37 pm | News | Comments

New research described details of how a diabetes-related gene functions on a biological pathway that affects the release of insulin. The study authors say that finding drugs that act on that pathway may eventually lead to a new treatment for type 1 diabetes. Read more...

Researchers Discover Tumor Growth, Angiogenesis Inhibitor

June 19, 2014 3:12 pm | News | Comments

A previously unknown variant of an extensively studied protein has been found to inhibit the growth of tumors and slow the development of new blood vessels necessary for cancers to metastasize, according to Cleveland Clinic research published in Cell. Read more...

Protalix Enrolls First Gaucher Patient in Phase 2 Trial

June 19, 2014 3:07 pm | News | Comments

Protalix BioTherapeutics Inc. announced that the first Gaucher patient has been enrolled in the company's Phase 2a clinical trial of oral glucocerebrosidase (PRX-112), the company's proprietary plant cell expressed form of an active glycosylated glucocerebrosidase enzyme. Read more...

Apitope Starts Preclinical Studies of Graves' Disease Drug

June 19, 2014 3:00 pm | News | Comments

Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced that it has started preclinical development of its novel peptide therapy ATX-GD-459 for the treatment of Graves' disease. Read more...

Debiopharm Kicks Off Phase 1 Study of MRSA Antibiotic

June 19, 2014 2:55 pm | News | Comments

Debiopharm Group announced the launch of a Phase 1 dose-escalation study of Debio 1450, a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus and vancomycin-intermediate S. aureus. Read more...

Stanford’s Technique Promises to Speed Up Drug Discovery

June 19, 2014 2:49 pm | News | Comments

Think of the human body as an intricate machine whose working parts are proteins: molecules that change shape to enable our organs and tissues to perform tasks such as breathing or eating or thinking. Of the millions of proteins, 500 in the kinase family are particularly important to drug discovery. Read more...

Aratana Kicks Off Real World Study of Canine Lymphoma Drug

June 19, 2014 11:47 am | News | Comments

Aratana Therapeutics Inc., a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, announced that it is currently enrolling patients in two nationwide clinical trials to evaluate its monoclonal antibody for canine T-cell lymphoma, AT-005. Read more...

Gene Mutations Protect Against Heart Disease

June 19, 2014 11:40 am | by Broad Communications | News | Comments

By scouring the DNA of thousands of patients, researchers at the Broad Institute, Massachusetts General Hospital, and their colleagues have discovered four rare gene mutations that not only lower the levels of triglycerides, a type of fat in the blood, but also significantly reduce a person's risk of coronary heart disease — dropping it by 40%. Read more...

Pfizer Posts Positive Two-Year Results for RA Drug

June 19, 2014 11:32 am | News | Comments

Pfizer Inc. announced the publication of two-year results from the ORAL Start study - a 24-month Phase 3 study in patients with moderately to severely active rheumatoid arthritis who had not previously received methotrexate - in the The New England Journal of Medicine. Read more...

NIH Launches 3-D Print Exchange

June 19, 2014 11:24 am | News | Comments

The National Institutes of Health has launched the NIH 3-D Print Exchange, a public website that enables users to share, download and edit 3-D print files related to health and science, such as custom laboratory equipment and models of bacteria and human anatomy. Read more...

Microbial 'Assembly Line' Makes Antibiotics, Other Drugs

June 19, 2014 11:15 am | News | Comments

Researchers at the University of Michigan have obtained for the first time three-dimensional snapshots of the “assembly line” within microorganisms that naturally produces antibiotics and other drugs, but the structure was not what the scientists had anticipated. Read more...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading